Wegovy Hair Loss & Telogen Effluvium: Honest Evidence Review

Hair loss on Wegovy is one of the most-searched concerns for new semaglutide 2.4 mg patients, and the honest read of the evidence is more reassuring than the search-suggest results imply. The Wegovy prescribing information^[4] lists alopecia at 3.3% on Wegovy 2.4 mg versus 1.0% on placebo in STEP-1^[1], with a striking sex skew (4% of women, 0.9% of men) and a higher rate (5.8%) reported at the newer 7.2 mg dose tier. STEP-4 (the maintenance trial)^[2] and SELECT (the cardiovascular-outcomes trial)^[3] both confirm alopecia as a treatment-emergent adverse event that surfaces during the active weight-loss phase and is not a chronic ongoing toxicity. The far more useful framing is the one a dermatologist would give you: this is telogen effluvium — the same temporary shedding pattern that follows pregnancy, bariatric surgery, severe COVID, high fever, major surgery, and any other rapid weight-loss episode^[5][6]. It is not a drug-direct toxicity, it is not scarring, it is not permanent, and it resolves on its own within 6-12 months as weight stabilizes.

The honest short answer for Wegovy patients

If you are reading this between months 2 and 6 of Wegovy therapy and noticing more hair in the shower drain, the most likely explanation is straightforward: your body is undergoing a synchronized telogen-effluvium episode triggered by the rapid weight loss the 2.4 mg dose drives. The Wegovy label^[4] reports alopecia in 3.3% of STEP-1 participants on 2.4 mg vs 1.0% on placebo — a statistically and clinically meaningful 2.3 percentage-point absolute increase that puts the number-needed-to-experience at roughly 1 in 43 patients. The female-only rate (4%) is more than four times the male rate (0.9%), reflecting both baseline iron status and the visibility of shed in longer hair styles.

The reassuring part: this is not Wegovy attacking your hair follicles. It is your hair cycle responding to a sudden systemic stressor — the same way it responds 3 months after childbirth, 3 months after bariatric surgery, and 3 months after a severe COVID infection. The follicles are intact, the regrowth is coming, and the timeline is predictable.

What STEP-1, STEP-4, and SELECT actually measured

Three trials anchor the Wegovy alopecia picture:

STEP-1 (Wilding 2021 NEJM):^[1] 1,961 adults with BMI ≥30 (or ≥27 with weight-related comorbidity) randomized 2:1 to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight reduction was −14.9% on semaglutide vs −2.4% on placebo. The publication's adverse-event table and the FDA label that followed report alopecia in 3.3% of the semaglutide arm vs 1.0% of placebo, with the female-specific rate at 4.0% and male-specific rate at 0.9%. This is the canonical Wegovy hair-loss number cited by every clinician and patient resource.

STEP-4 (Rubino 2021 JAMA):^[2] a randomized withdrawal trial designed to answer whether weight loss is maintained on continued semaglutide. After a 20-week open-label run-in on semaglutide 2.4 mg (mean weight loss −10.6%), 803 participants were randomized to continue semaglutide or switch to placebo for a further 48 weeks. The continued-semaglutide group lost an additional −7.9% body weight; the placebo-switch group regained +6.9%. The practical implication for hair: continued therapy at a stable weight (rather than discontinuation that triggers regain) is the better path. Stopping Wegovy does not accelerate hair recovery and may actually slow it by introducing a new physiologic stressor.

SELECT (Lincoff 2023 NEJM):^[3] 17,604 adults with established cardiovascular disease and overweight or obesity (but without diabetes) randomized to semaglutide 2.4 mg or placebo and followed for a mean of 39.8 months. The primary outcome was a 20% relative reduction in major adverse cardiovascular events. For the side-effect story, SELECT's sheer scale and duration matter: the trial provides the largest, longest-duration safety dataset for semaglutide 2.4 mg ever published, and the adverse-event profile remained consistent with the STEP program — alopecia as a treatment-emergent AE present during the weight-loss phase, not a chronic ongoing process at maintenance weight.

It's telogen effluvium, not direct drug toxicity

The clinical syndrome behind every “Wegovy hair loss” report is telogen effluvium — the textbook hair-cycle disturbance described in the Hughes, Syed & Saleh StatPearls chapter^[5] that every dermatology resident reads. Normal scalp hair cycles through three phases: anagen (growing, 2-7 years), catagen (regressing, ~2-3 weeks), and telogen (resting/shedding, ~3 months). At any moment, roughly 85-90% of follicles are in anagen and 10-15% are in telogen. A systemic stressor — rapid weight loss, childbirth, high fever, major surgery, severe illness, crash dieting — can synchronize a large fraction of follicles into telogen at the same time. Three months later, those follicles shed simultaneously, producing a sudden noticeable increase in hair on the pillow, in the shower drain, and in the brush.

Three features distinguish telogen effluvium from the more worrying patterns:

• Diffuse, not patchy. Hair thins evenly across the entire scalp. Discrete bald patches point toward alopecia areata (autoimmune) and need a different workup^[5].
• Non-scarring. The follicles are still alive and structurally intact — they've just paused. A scarring alopecia (red, painful, or shiny smooth patches) destroys the follicle permanently and needs a dermatology biopsy.
• Self-limiting. When the systemic stressor resolves, the follicles re-enter anagen and regrow. Recovery is the rule, not the exception^[5].

The mechanism is not semaglutide binding to a hair- follicle receptor and killing keratinocytes. There is no evidence in the published GLP-1 receptor pharmacology literature for a direct toxic effect on the hair shaft or the dermal papilla. The mechanism is the rapid drop in caloric intake during the dose-escalation weeks, the temporary protein deficit during the first months of severe appetite suppression, and the lean-mass loss that accompanies any rapid weight reduction^[8] — collectively a strong telogen-effluvium trigger by any standard definition^[5][6].

Why Wegovy's rate exceeds Ozempic's

Wegovy and Ozempic are the same molecule — semaglutide — but the brands are dosed differently and produce different weight-loss magnitudes. Ozempic is dosed 0.5-2.0 mg weekly for type 2 diabetes and produces roughly 6-10% TBWL at the maximum dose in the SUSTAIN trials. Wegovy is dosed 2.4 mg weekly for chronic weight management and produced −14.9% mean TBWL in STEP-1^[1]. The newer 7.2 mg Wegovy dose (approved for higher-magnitude weight loss) produces an even larger reduction.

Alopecia rates track the weight-loss magnitude, not the molecule:

• Ozempic 0.5-2.0 mg (T2D dose tier): alopecia listed only in Section 6.2 Postmarketing Experience, not the main clinical-trial AE table. Rate cannot be reliably estimated from spontaneous- reporting data, but the SUSTAIN-1 monotherapy trial did not surface alopecia at the ≥5% adverse-event threshold.
• Wegovy 2.4 mg (STEP-1 cosmetic dose): alopecia in 3.3% vs 1.0% placebo over 68 weeks, with 4% female / 0.9% male reporting rates^[4].
• Wegovy 7.2 mg (STEP UP higher-magnitude dose): alopecia in 5.8% vs 1.0% placebo, a continued dose-response signal that lines up with the rapid-weight-loss attribution rather than any receptor- binding mechanism.

The takeaway: switching from Ozempic to Wegovy will increase your weight-loss magnitude and may also increase your likelihood of an alopecia episode. Switching from Wegovy back to Ozempic during an active telogen-effluvium episode will not reverse hair already in telogen but may reduce the magnitude of additional shedding by slowing the rate of ongoing weight loss.

Why Wegovy's rate is lower than tirzepatide's

On the other side of the comparison, tirzepatide (Zepbound at the 15 mg cosmetic dose) reports alopecia at roughly 5% vs ~1% placebo in SURMOUNT-1^[7]— about 1.5 times the Wegovy 2.4 mg rate. Again, this is not because tirzepatide is somehow more toxic to hair as a molecule. Tirzepatide is a dual GIP/GLP-1 agonist, but neither receptor is expressed on hair follicles in any clinically meaningful density.

The difference is the weight-loss magnitude. SURMOUNT-1 reported mean −20.9% TBWL at Zepbound 15 mg over 72 weeks; STEP-1 reported −14.9% on Wegovy 2.4 mg over 68 weeks. Larger, faster weight loss synchronizes more follicles into telogen. Patients losing the same magnitude of weight via bariatric surgery or very-low-calorie diet report essentially identical hair-shedding patterns — the rate-of-loss and total magnitude predict the hair signal regardless of the intervention.

Timeline: when it starts, peaks, and resolves

Telogen effluvium has a remarkably consistent timing signature on Wegovy that's useful for setting expectations:

• Weeks 0-16 (dose titration): the Wegovy titration ramps from 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks. Rapid appetite suppression and a sharp drop in caloric intake begin during this phase. No visible hair changes yet — the follicles are shifting into telogen but haven't shed yet.
• Months 2-3: first shedding episode. Roughly 8-12 weeks after the rapid-weight-loss trigger, the synchronized telogen cohort sheds. Patients notice more hair on the pillow, in the shower, and in the brush. This is the classic delayed onset of telogen effluvium^[5].
• Months 3-6: peak shedding. The most dramatic phase, often coinciding with reaching the 2.4 mg maintenance dose around week 16-20. Daily shed counts can double or triple normal baseline.
• Months 6-12: spontaneous resolution. As weight stabilizes (the typical STEP-1 weight-loss curve plateaus around month 12), the telogen cohort completes its cycle and new anagen hairs regrow. Regrowth is visible first as short bristly new hairs along the hairline and part line.
• Months 12-18: full recovery for most patients. Hair density returns to the pre-treatment baseline, though the regrown hairs may take 2+ years to reach their previous length.

The Kang 2024 single-center retrospective study^[6] of telogen effluvium specifically tied to weight loss documented this same time course in a non-GLP-1 cohort — reinforcing that the mechanism is the rapid weight loss, not the drug.

Same mechanism as post-pregnancy, post-bariatric, post-COVID hair loss

The single most useful reframe for an anxious Wegovy patient is this: the hair loss you're experiencing is biochemically identical to what happens 3 months after giving birth, 3 months after bariatric surgery, and 3 months after a severe COVID infection or hospitalization. Every one of those scenarios shares the same mechanism — a sudden systemic stressor synchronizes the hair cycle — and every one of those scenarios shows the same timing signature and the same self-limiting recovery^[5].

Bariatric surgery patients in particular show a near- universal telogen effluvium episode 3-6 months after Roux-en-Y gastric bypass or sleeve gastrectomy. The dermatology literature on this is well-established and the patient counseling is identical: it's expected, it's temporary, focus on protein and micronutrient adequacy, and the hair grows back. Post-pregnancy telogen effluvium (sometimes called “postpartum hair loss”) is recognized as so common — affecting 40-50% of new mothers — that obstetricians routinely warn patients about it during prenatal visits. The COVID-19 pandemic produced a wave of telogen effluvium 3 months after infection that briefly made dermatology headlines^[5] and again followed the same playbook.

For a Wegovy patient, the “Wegovy caused my hair loss” framing is technically true in the sense that Wegovy enabled the rapid weight loss that triggered the telogen shift — but the same hair loss would occur from any other weight-loss intervention producing the same magnitude of TBWL over the same timeframe.

Practical interventions: protein, iron, vitamin D

Three nutritional interventions have actual evidence behind them for supporting hair during rapid weight loss. None of them are a hair-loss treatment in the FDA sense — they support the underlying physiology so the telogen-effluvium episode runs its natural course without being prolonged by frank micronutrient deficiency.

Protein: 1.2-1.6 g/kg lean body mass per day

The Look 2025 DXA body-composition analysis of SURMOUNT-1^[8] demonstrated that tirzepatide patients lost ~10% of their lean body mass alongside the headline ~21% TBWL — meaning roughly one-quarter of the weight lost was lean tissue, not fat. The same lean- mass loss pattern is documented in semaglutide trials, including STEP-1^[1]. Hair follicles are protein-synthesis-intensive (the hair shaft is ~90% keratin), and inadequate dietary protein during rapid weight loss is a recognized contributor to telogen effluvium severity^[5].

The evidence-based target for adults on Wegovy is 1.2-1.6 g of protein per kg of lean body mass per day. For a 200 lb patient with ~30% body fat (lean mass ~63 kg), that translates to roughly 75-100 g of protein per day — meaningfully higher than the 0.8 g/kg RDA used for sedentary adults at weight maintenance. Practical sources: 4-6 oz of cooked salmon (28-42 g), Greek yogurt (15-17 g per cup), eggs (6 g each), tuna (25 g per 3-oz can), chicken breast (26 g per 3 oz), cottage cheese (24 g per cup), and whey or plant-based protein powders (20-25 g per scoop) when whole-food intake is appetite-suppressed below target.

Iron and ferritin: get a lab panel

The Durusu Turkoglu 2024 J Cosmet Dermatol study^[11] of biochemical status in telogen effluvium patients examined ferritin alongside hemoglobin, B12, vitamin D, thyroid function, zinc, copper, biotin, and selenium. Iron deficiency — specifically low ferritin (the iron storage protein) — is the most-replicated micronutrient deficiency tied to telogen effluvium in the literature. Women with menstrual blood loss are at higher baseline risk and account for much of the sex skew in the Wegovy alopecia rate (4% women vs 0.9% men).

A reasonable lab panel for a patient with new shedding on Wegovy includes: CBC, ferritin, iron + TIBC, 25-hydroxyvitamin D, B12, TSH. The threshold for ferritin supplementation in the dermatology literature is often cited as <30 ng/mL for symptomatic patients (vs the standard lab-reported “normal” range starting at ~10-15 ng/mL). If labs are abnormal, treat the deficiency — iron orally with vitamin C for absorption, vitamin D 1,000-2,000 IU daily, B12 if borderline-low. Do not start empiric iron supplementation without labs — iron overload is also harmful.

Vitamin D, zinc, and selenium: cover the basics

Vitamin D deficiency is independently common in patients with obesity and is associated with telogen effluvium in the Durusu Turkoglu cohort^[11]. Most US adults benefit from 1,000-2,000 IU daily, particularly during winter months and for patients with limited sun exposure. Zinc and selenium adequacy is best achieved through a varied diet rather than high-dose supplementation — excess zinc can paradoxically cause hair loss and excess selenium is frankly toxic.

Biotin overhype — what the evidence actually shows

The supplement aisle is full of biotin-branded hair-growth products marketed at 5,000-10,000 mcg per dose — roughly 170-330 times the 30 mcg adequate intake. The Patel, Swink & Castelo-Soccio 2017 Skin Appendage Disorders review^[9] systematically examined the evidence for biotin supplementation in hair loss and reached a clear conclusion: biotin supplementation in non-deficient patients does not improve hair growth. The studies showing benefit were either in patients with verified biotin deficiency (rare, typically caused by inborn errors of metabolism or prolonged raw-egg-white ingestion) or in combination formulations where biotin was bundled with actual active ingredients.

The Trüeb 2018 follow-up comment^[10] in the same journal reinforced the point: the marketing claims for high-dose biotin are not supported by controlled clinical evidence in immunocompetent adults eating a standard Western diet. The Durusu Turkoglu 2024 cohort^[11] specifically measured biotin levels in telogen effluvium patients and did not find a deficiency pattern driving the syndrome.

There is one important practical harm to high-dose biotin that every Wegovy patient should know: biotin at 5,000+ mcg doses interferes with immunoassay-based laboratory tests — including thyroid function tests, troponin (the primary cardiac biomarker used in emergency departments to evaluate chest pain), and several hormone assays. The FDA has issued safety communications about falsely-low TSH and falsely-elevated free T4 results in patients on high-dose biotin, leading to misdiagnosis of hyperthyroidism. If you take biotin, stop it at least 72 hours before any bloodwork and tell your clinician.

Bottom line on biotin: it doesn't work for non- deficient adults, it interferes with critical lab tests, and the money is better spent on a protein source.

When to call your prescriber or see a dermatologist

Most Wegovy-related hair shedding is telogen effluvium and runs its natural course without medical intervention. The situations that do warrant a call to your prescriber or a dermatology referral:

• Patchy loss with discrete circular bald spots — suggests alopecia areata, an autoimmune condition that needs intralesional steroid injections or topical immunotherapy^[5].
• Scarring patches — red, painful, shiny, or smooth areas where the follicular openings have disappeared. This suggests a scarring alopecia (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia) and needs a punch biopsy for diagnosis — treatment within months matters because scarring is permanent.
• Receding hairline or crown thinning in a male pattern — suggests androgenetic alopecia (male-pattern or female-pattern hair loss), which is treatable with finasteride, minoxidil, or low-level laser therapy. This may be unmasked by but is not caused by Wegovy.
• Shedding lasting beyond 12 months after weight has stabilized — suggests chronic telogen effluvium or an unaddressed underlying driver (iron deficiency, thyroid disease, autoimmune disease).
• Associated symptoms — weight loss continuing beyond the expected curve, fatigue, cold intolerance, or palpitations — warrant a TSH and basic workup to rule out thyroid disease.

FAQ

Will my hair grow back after stopping Wegovy?

Yes, for telogen effluvium — the syndrome causing Wegovy-attributed hair loss — spontaneous regrowth is the rule. Recovery typically takes 6-12 months after weight stabilizes, regardless of whether you continue or stop the medication. STEP-4 showed that withdrawal triggers weight regain (+6.9% over 48 weeks)^[2], which is itself a metabolic stressor — stopping is not required for regrowth and may not even be beneficial.

Does Wegovy itself damage hair?

No. There is no published evidence for a direct toxic effect of semaglutide on the hair follicle, the hair shaft, or the dermal papilla. The mechanism is indirect — rapid weight loss synchronizes the hair cycle into a temporary telogen shedding phase, the same mechanism that causes post-pregnancy, post-bariatric, and post-COVID hair loss.

Why is hair loss more common in women on Wegovy?

The Wegovy label^[4] reports alopecia in 4% of women vs 0.9% of men on 2.4 mg. This mirrors the well- established female predominance of telogen effluvium in the general dermatology literature^[5], driven by baseline iron status (menstrual blood loss), hormonal sensitivity of the hair cycle, and longer hair making shed more visible.

Why is Wegovy's rate higher than Ozempic's?

Same molecule, different dose and different weight-loss magnitude. Wegovy 2.4 mg drives mean −14.9% TBWL in STEP-1^[1]; Ozempic at the 0.5-2.0 mg type-2 diabetes dose tier drives roughly 6-10% TBWL. Alopecia rates track weight-loss magnitude, so the 2.4 mg dose registers 3.3% in the main label table while the lower doses appear only in postmarketing experience.

Should I take biotin?

Probably not. The Patel 2017 review^[9] found no benefit for biotin supplementation in non-deficient adults, and high-dose biotin interferes with thyroid and cardiac lab tests. Spend the money on a protein source instead.

Should I get bloodwork?

Yes — CBC, ferritin, 25-hydroxyvitamin D, B12, and TSH at minimum. Iron deficiency is the most-replicated micronutrient driver of telogen effluvium and is treatable. Do not start empiric iron supplementation without confirming the deficiency.

What about the new oral Wegovy pill?

The 2026-approved oral semaglutide formulation for chronic weight management delivers the same molecule at a clinically equivalent exposure. The alopecia mechanism (rapid weight loss synchronizing hair follicles into telogen) is identical regardless of injection vs oral route, and the dose-tier comparison still applies: the higher the cosmetic weight- loss magnitude, the higher the alopecia reporting rate.

Does Wegovy cause hair loss in adolescents on STEP TEENS?

Pediatric prescribing information for Wegovy in adolescents 12 years and older includes alopecia in the adverse-event profile, though pediatric reporting rates may differ from the adult numbers. The mechanism is the same — rapid weight loss synchronizing hair follicles — and the same protein and micronutrient counseling applies. Confirm current adolescent rates against the live DailyMed label^[4] with your prescriber.

Will switching from Wegovy to Zepbound or Mounjaro stop it?

No — the mechanism is rapid weight loss, not the specific drug, so all of the GLP-1 and dual-agonist weight-loss medications carry the same telogen-effluvium risk. Zepbound at the 15 mg cosmetic dose actually carries a slightly higher reported rate (~5% in SURMOUNT-1) than Wegovy 2.4 mg (3.3%) because it drives larger weight loss. Mounjaro at the lower type-2 diabetes dose tier does not list alopecia in its main clinical-trial adverse-event table.

Related research and tools

• The Ozempic sister article on semaglutide hair loss covers the same molecule at the lower T2D dose tier and the SUSTAIN-1 evidence base.
• The tirzepatide twin (Zepbound and Mounjaro) covers the same mechanism with SURMOUNT-1 alopecia rates and why tirzepatide rates run slightly above semaglutide (proportional to the larger weight-loss magnitude).
• The parent guide to GLP-1 fatigue and hair loss duration covers the same hair-loss pattern across the full GLP-1 class.
• What the STEP and SURMOUNT trials actually reported for the full adverse-event profile.
• The GLP-1 side effect Q&A hub for the most-asked patient questions across the side- effect landscape.
• Resistance training to preserve lean mass on GLP-1s — the strongest non-nutritional lever for limiting lean-mass loss during rapid weight reduction.
• Interactive GLP-1 side-effect timeline tool to see when each side effect peaks and resolves by drug and week.
• GLP-1 protein calculator for a personalized daily protein target.